Европейская академия естественных наук Hannover E.V.

Kexing Wu

Kexing Wu, Ph.D. in Medicine from the University of Cambridge, currently serves as the Chief Scientific Strategic Advisor at Grand Pharmaceutical Group (China) Limited. He is the founder, chairman, and CEO of China Shanghai Hangshen Biotech Co., Ltd.

Under his leadership, the team has developed original self-assembling particle carrier delivery technologies such as SapRNA™, reRNA™ (self-replicating modified RNA strategy), and haloMCs™ (original modular protein modification system), with over 20 related invention patents. The groundbreaking reRNA™ technology developed by the team is the world's first to achieve self-amplification of RNA within cells using a negative-strand RNA virus replicon, enabling efficient and prolonged protein expression while maintaining the "dynamic stability" of nucleic acids. The modular protein modification system, haloMCs™, is compatible with SapRNA™ and offers a range of functions, including altering subcellular protein localization, reshaping protein structure, and providing antigen presentation. It ensures both safety and improved delivery efficiency and targeting. The SapRNA™ technology has broken the global patent monopoly in this field (mRNA modification, LNP delivery), serving as a novel RNA drug development system that compensates for the limitations of mRNA technology. It has broad applications in areas such as cancer treatment, vaccine development, and protein replacement, offering promising prospects. SapRNA™ has surpassed the industry bottlenecks represented by mRNA in terms of expression, delivery, and production, emerging as a superior solution in the RNA field.

Dr. KEXING WU is guided by the principle of "addressing the urgent clinical needs and preventing diseases". Under his leadership, the team has been working diligently to tackle and overcome global clinical challenges. Leveraging SapRNA™ technology, the team has developed both therapeutic and preventive vaccines, both of which are at the forefront of international research. The SapRNA™-KRAS, a T-cell tumor therapy vaccine designed for KRAS mutations, has become the industry leader in global immune therapy for targeting KRAS mutant tumors. It offers new hope to patients with drug-resistant KRAS mutant tumors. The B-cell preventive vaccine aims to transform late-stage disease treatment into early prevention, preventing problems before they occur and benefiting the public. Furthermore, the team has developed the oncolytic immunotherapy drug Revottack®, based on the negative-strand RNA elastic virus. It has achieved breakthrough results in both domestic and international clinical trials using intravenous injection. This addresses the unmet need for treatment in a patient population without any existing therapies, highlighting its high clinical value.

The self-assembling particle carrier delivery technology, SapRNA™, created by Dr. KEXING WU and his team, features unique technical characteristics and a differentiated product pipeline strategic layout. It has received numerous honors, including the "2022 China Biomedical Technology Innovation Value List", "Ernst & Young Fudan Most Potential Enterprise", and the Top-Level Project of "High-Level Talents Innovation and Entrepreneurship Program" in Qiantang District, Zhejiang Province in 2023. Meanwhile, the world-leading platform technology is also highly regarded by renowned pharmaceutical companies and research institutions at home and abroad. The team has entered into strategic partnerships with Grand Pharmaceutical and Junshi Biosciences. In addition, Dr. KEXING WU's team will establish joint laboratories with international research institutions to conduct collaborative research and development on innovative global products, ensuring that the SapRNA™ platform technology can benefit more patients.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт